Advanced age is not a barrier to creating a functional arteriovenous fistula: a retrospective study

医学 回顾性队列研究 动静脉瘘 瘘管 血液透析 队列 糖尿病 单中心 外科 内科学 内分泌学
作者
Monica Beaulieu,Chance S. Dumaine,Alexandra Romann,Mercedeh Kiaii
出处
期刊:Journal of Vascular Access [SAGE]
卷期号:18 (4): 307-312 被引量:11
标识
DOI:10.5301/jva.5000710
摘要

Introduction Arteriovenous fistulas (AVFs) are the recommended form of vascular access for hemodialysis. However, controversy exists regarding whether AVFs are suitable for elderly patients. Methods Single-center retrospective review to investigate the impact of age on AVF outcomes. Five hundred and twenty-five patients with AVF creation were stratified based on age <65, 65-75, and >75 years. AVF outcomes including primary failure, AVF patency (primary, secondary, and functional), and AVF complications were studied for 3 years following AVF creation. Results The cohort was 63% male, 44% Caucasian, and 55% had diabetes or cardiovascular disease. 39% were aged <65 years, 33% 65-75 years, and 28% were aged >75 years. No differences in rates of primary failure, loss of primary patency, complications, or need for intervention were observed between age groups. There was a significant association of age with secondary patency and functional patency, with age >75 being an independent risk factor for shortened lifespan of the fistula. For patients aged >75 years, secondary patency at 3 years was 64% compared to 75%-78% for younger patients. Functional patency at 2 years was 69% for those aged >75 years compared to 78%-81% for younger patients. Conclusions We found no difference in AVF maturation, primary patency, complications, or interventions in those over the age of 75 compared to younger counterparts. While secondary and functional patency rates were significantly lower in those aged >75 years, the magnitude of difference is likely not clinically relevant. Therefore, we recommend that advanced age alone should not preclude patients from AVF creation.

科研通智能强力驱动
Strongly Powered by AbleSci AI

祝大家在新的一年里科研腾飞
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1⑩完成签到,获得积分20
1秒前
王歪歪完成签到,获得积分10
2秒前
善学以致用应助tassssadar采纳,获得10
4秒前
高级后勤完成签到,获得积分10
4秒前
天天小女孩完成签到 ,获得积分10
6秒前
星辰大海应助sainanTang采纳,获得10
6秒前
林登万完成签到,获得积分10
7秒前
ding应助1⑩采纳,获得10
7秒前
凯卮完成签到,获得积分10
8秒前
David完成签到,获得积分10
9秒前
学茶小白完成签到,获得积分10
9秒前
fly完成签到,获得积分10
10秒前
yuki完成签到,获得积分10
10秒前
柑橘完成签到,获得积分10
10秒前
humorr完成签到,获得积分10
11秒前
棵虫完成签到,获得积分10
11秒前
恶恶么v完成签到,获得积分10
13秒前
莫等闲完成签到,获得积分10
13秒前
HMR完成签到 ,获得积分10
13秒前
橙子完成签到 ,获得积分10
13秒前
mature0821完成签到,获得积分10
15秒前
16秒前
daqing完成签到,获得积分10
16秒前
NexusExplorer应助肌肉干细胞采纳,获得10
18秒前
19秒前
23秒前
24秒前
奶油蜜豆卷完成签到,获得积分10
24秒前
???发布了新的文献求助10
24秒前
liuchao完成签到,获得积分10
26秒前
26秒前
ColdPomelo完成签到,获得积分10
26秒前
CC完成签到 ,获得积分10
26秒前
时代更迭完成签到 ,获得积分10
28秒前
怡然白竹完成签到 ,获得积分10
30秒前
wintersss完成签到,获得积分10
32秒前
tassssadar完成签到,获得积分10
37秒前
AdventureChen完成签到 ,获得积分10
38秒前
38秒前
威武画板完成签到 ,获得积分10
39秒前
高分求助中
Востребованный временем 2500
The Three Stars Each: The Astrolabes and Related Texts 1500
Classics in Total Synthesis IV: New Targets, Strategies, Methods 1000
Les Mantodea de Guyane 800
Mantids of the euro-mediterranean area 700
The Oxford Handbook of Educational Psychology 600
有EBL数据库的大佬进 Matrix Mathematics 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 内科学 物理 纳米技术 计算机科学 遗传学 化学工程 基因 复合材料 免疫学 物理化学 细胞生物学 催化作用 病理
热门帖子
关注 科研通微信公众号,转发送积分 3413470
求助须知:如何正确求助?哪些是违规求助? 3015836
关于积分的说明 8872004
捐赠科研通 2703591
什么是DOI,文献DOI怎么找? 1482357
科研通“疑难数据库(出版商)”最低求助积分说明 685250
邀请新用户注册赠送积分活动 679988